BHVN's Troriluzole awaits pivotal FDA approval in 2025, backed by $600M funding. Explore its diverse pipeline and promising ...

The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S.

Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

A recent review in Frontiers of Neurology noted these therapies are available: Riluzole (Rilutek) – An oral medication that decreases cellular excitotoxicity caused by excess glutamate (a ...

May is recognized as ALS Awareness Month, offering an opportunity to raise awareness, deepen public understanding, and ...

The third ALS treatment to be given FDA approval, following Mitsubishi Tanabe’s Radicava ($170,000 per year) and generic drug riluzole – Relyvrio is priced at around $12,500 per 28-day ...

and generic drug riluzole, sold as Rilutek by Sanofi. Trump's 2026 budget request envisages sweeping cuts to funding for the NIH and other federal agencies that will be a disaster, say science ...